Invited Speakers


1. Alex Wlodawer  – National Cancer Institute, Frederick, USA
The importance of the non-catalytic domains of Janus kinases
2. Dario Alessi – Dundee, UK
Regulation and function of the LRRK2 Parkinson’s disease protein kinase
3. Richard Bayliss
Allosteric regulation of Aurora-A kinase
4. Roux Benoit – University of Chicago, USA
Kinetics of kinase inhibitor binding
5. Natasja Brooijmans
Free energy methods in advancing kinase projects
6. Christian Doerig – Monash University, Australia
Malaria: the kinomes of both the parasite and its host erythrocyte as targets
7. Doriano Fabbro – PIQUR Therapeutics AG, Basel, Switzerland
8. Jon Erickson – Eli Lilly, Indianapolis, USA
Computational approaches to kinase discovery, potential discovery story
9. Eric S. Fischer – Dana-Farber Cancer Institute/Harvard Medical School, UK
Large Scale Proteomics Approaches to Accelerate Degrader Development for Kinases and other Challenging Targets in Cancer
10. Beata Jagielska
Protein kinases inhibitors as drugs for targeting cancer
11. Jenna Jewel
12. Jolanta Jura
MAP- kinase dependent regulation of transcripts stability triggered by MCPIP
13. Natalia Jura
Receptors kinases – from structure to signaling mechanisms
14. Eileen Kennedy
15. Stefan Knapp – Johann-Wolfgang Goethe University, Frankfurt, Germany
Strategies for the rational design of selective kinase inhibitors kinase structure and chemical probes for untapped kinases
16. Stefan Laufer – Tuebingen, Germany
Targeting the R-Spine: Design, Synthesis and Biological Evaluation of Novel Type I½ p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency and Prolonged Target Residence Time: Implication for Cancer- and CNS-Applications
17. Lorenzo Pinna – University of Padua, Italy.
How to get out without protein kinase CK2: the survival strategy of CK2 knockout cells
18. Michal Vieth – Eli Lilly and Company Lilly Research Laboratories, Indianapolis, USA
19. Jeremy Mottram
20. Gerhard Mueller – Gotham Therapeutics, New York, USA
Optimizing binding kinetic signatures of kinase inhibitors: facts of fantasy?
21. Natarajan Kannan – University of Georgia, USA
Evolution of allosteric regulation in tyrosine kinases and implications for personalized medicine
22. Alexandra Newton – University of California, San Diego, USA
PKC and its biology
23. Joanna Niemiec
Trastuzumab in adjuvant setting applied for HER-2 positive breast cancer patients- Cracov experience.
24. Krzysztof Pawlowski – Warsaw University of Life Sciences, Poland
Novel kinase and pseudokinase families throughout the tree of life. Structural bioinformatics view on evolution of a superfamily
25. Tomasz Sarnowski – Institute of Biochemistry and Biophysics Polish Academy of Sciences, Warsaw, Poland
Targeting of chromatin remodeling complexes and metabolome-related kinases in cancer
26. Susan Taylor – Taylor Laboratory, San Diego, USA
PKA: Dynamic Switches and Disease
27. Vincent Tagliabracci  – University of California, San Diego, USA
Phosphorylation of secreted proteins by a new family of kinases
28. Andrew Tobin – University of Glasgow, UK
Chemical genetic approaches to defining the function of phospho-signalling cascades

29. Sandhya S. Visweswariah – Indian Institute of Science, Bangalore, India / University of Bergen, Norway
Pseudokinase domain in receptor GCs
30. Matthias Wymann
Precision drugs – novel tools to target PI3K-mTOR pathways in metabolism and cancer

Comments are closed